顺铂加多西他赛同期放化疗晚期鼻咽癌的临床研究

目的：探讨顺铂加多西他赛同期放化疗和单纯放疗两种方法对晚期鼻咽癌的临床效果和毒副反应。方法：将60例经病理证实的局部晚期鼻咽癌（T3—4N1—3M0）共随机分为单纯放疗组（对组照）30例和同期放化组（放化组）30例。单纯放疗组（对组照）：采用连续照射，每周5次，每次照射2Gy，使鼻咽平均剂量70Gy／7周（66～74Gy），颈部平均剂量65Gy／6．5周（50～72Gy）。同期放化组（放化组）：在单纯放疗组的基础上加多西他赛联合顺铂同期化疗，顺铂20mg／m^2，静脉滴注d1～4，多西他赛60mg／甜，静脉滴注d1，每3周为一个疗程，共2个疗程。结果：两组患者同期有效率对照组93．3％、放化组100％，治疗后随访3年生存率对照组70．0％、放化组86．7％。3年复发率对照组10．0％（3例）、放化组3．33％（1例）。结论：顺铂加多西他赛同期放化疗在治疗晚期鼻咽癌的临床疗效上优于单纯放疗。

Cisplatin combined with Docetaxel and concomitant radiation therapy treatment of advanced nasopharyngeal carcinoma

Objective： To investigate cisplatin combined with docetaxel and concomitant radiation therapy and two received radiotherapy for advanced nasopharyngeal cancer treatment clinical effect and toxicity. Methods： 60 patients with pathologically confirmed locally advanced nasopharyngeal carcinoma （T3 - 4N1 - 3M0 ） were randomly assigned radiotherapy alone group （for group photos） 30 cases and the same chemoradiotherapy group （Radiochemical group） of 30 cases. Radiotherapy alone group （for group photo） ： Using a continuous exposure, 5 times a week, each irradiation 2 Gy, the average dose to the nasopharynx 70 Gy / 7 weeks （66 - 74 Gy）, neck average dose 65Gy/6. 5 weeks （ 50 - 72Gy）. Over the same period chemoradiotherapy group （chemoradiotherapy group） ： In the radiotherapy alone group on the basis of his race Jiaduo Xi same chemotherapy combined with cisplatin, cisplatin 20mg/ m^2, intravenous drip d1 - 4, docetaxel 60mg/m^2, intravenous infusion dl, every 3 weeks for a course of treatment, a total of 2 courses. Results： The patients in the control group during the same period the efficiency of 93. 3%, up 100% of group treatment were followed up for 3 - year survival rate in control group 70. 0%, up 86. 7% of group. 3 - year recurrence rate in the control group 10. 0% （3 cases）, complications were 3. 33 % （ 1 case）. Conclusion： Cisplatin combined with Docetaxel and concomitant radiation therapy in the treatment of advanced nasopharyngeal carcinoma effect better than that radiotherapy alone.